Cargando…
Are there clinical factors that can predict prolonged survival of patients receiving olaparib as maintenance therapy for BRCA-mutated ovarian cancer?
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798247/ https://www.ncbi.nlm.nih.gov/pubmed/35117386 http://dx.doi.org/10.21037/tcr.2019.12.102 |
| _version_ | 1784641754533724160 |
|---|---|
| author | Lieberman, Howard B. |
| author_facet | Lieberman, Howard B. |
| author_sort | Lieberman, Howard B. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8798247 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-87982472022-02-02 Are there clinical factors that can predict prolonged survival of patients receiving olaparib as maintenance therapy for BRCA-mutated ovarian cancer? Lieberman, Howard B. Transl Cancer Res Editorial Commentary AME Publishing Company 2020-02 /pmc/articles/PMC8798247/ /pubmed/35117386 http://dx.doi.org/10.21037/tcr.2019.12.102 Text en 2020 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/. |
| spellingShingle | Editorial Commentary Lieberman, Howard B. Are there clinical factors that can predict prolonged survival of patients receiving olaparib as maintenance therapy for BRCA-mutated ovarian cancer? |
| title | Are there clinical factors that can predict prolonged survival of patients receiving olaparib as maintenance therapy for BRCA-mutated ovarian cancer? |
| title_full | Are there clinical factors that can predict prolonged survival of patients receiving olaparib as maintenance therapy for BRCA-mutated ovarian cancer? |
| title_fullStr | Are there clinical factors that can predict prolonged survival of patients receiving olaparib as maintenance therapy for BRCA-mutated ovarian cancer? |
| title_full_unstemmed | Are there clinical factors that can predict prolonged survival of patients receiving olaparib as maintenance therapy for BRCA-mutated ovarian cancer? |
| title_short | Are there clinical factors that can predict prolonged survival of patients receiving olaparib as maintenance therapy for BRCA-mutated ovarian cancer? |
| title_sort | are there clinical factors that can predict prolonged survival of patients receiving olaparib as maintenance therapy for brca-mutated ovarian cancer? |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798247/ https://www.ncbi.nlm.nih.gov/pubmed/35117386 http://dx.doi.org/10.21037/tcr.2019.12.102 |
| work_keys_str_mv | AT liebermanhowardb arethereclinicalfactorsthatcanpredictprolongedsurvivalofpatientsreceivingolaparibasmaintenancetherapyforbrcamutatedovariancancer |